The Future of CPPD

There's millions of people with CPPD in the United States and a lack of pharmaceutical companies trying to go after that market. We need cohorts of patients that are engaged and that are ready to give us their perspective on how this disease is affecting them so that we know what we should be studying. And then I think the other thing that we can do in the meanwhile while that is incubating is also to understand more about the natural history of this disease, the different phenotypes, and the long-term outcomes of this disease outside of the joint.